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EDITORIALS
Three Roots of Melanoma
S EGURA ET AL
1 DESCRIBE MORPHOLOGIC FEA-
tures of melanomas with a nodular compo-
nent using in vivo reflectance-mode confo-
cal microscopy (RCM) and correlate these
RCM findings with histopathologic find-
ings. The most striking observation made by the inves-
tigators is the remarkable difference in epidermal
involvement between nodular melanoma (NM) and su-
perficial spreadingmelanoma (SSM)with a nodular com-
ponent. At RCM, SSMs frequently showed epidermal
disarrangement and pagetoid infiltration, whereas NMs
exhibited a preserved epidermal pattern and few paget-
oid cells.1 This new observation provides fertile ground
for revisiting the conventional concept of melanoma de-
velopment. We propose an alternative hypothesis based
on recent observations made in stem cell research and
demonstrate how this hypothesis can better account for
the observed clinical and epidemiologic differences be-
tween melanoma subtypes.
Many clinicians and researchers subscribe to the theory
that all cutaneousmelanomas arise from transformed epi-
dermal melanocytes. The malignant cells are thought to
initially proliferate along the basal layer (melanoma in
situ). After a variable period,which can range frommonths
to decades, the malignant melanocytes may acquire the
capacity to not only proliferate radially but also invade
See also page 1311
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Figure 1. Schematic model shows the origin of lentigo maligna, nodular melanoma, and superficial spreading melanoma from melanoma stem cells of the hair
follicle, the dermis, and the epidermal basal layer, respectively. Melanoma stem cells (yellow concentric ring) produce progenitor cells (green stars) that drive
proliferation and progression of melanoma cells (brown circles). A-C, Lentigo maligna deriving from stem cells of the outer sheet of the facial hair follicle.
D-F, Superficial spreading melanoma deriving from stem cells in the epidermal basal layer. G-I, Nodular melanoma deriving from dermal stem cells.
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vertically into the dermis (invasive melanoma). The
rapidity with which melanoma can invade the dermis
probably depends onmultiple factors including the pro-
liferative rate of the tumor cells, the degree of neoangio-
genesis, and the ability of the surrounding tumormicro-
environment to permit or impede the migration of
malignant cells.2 Based on clinical observations of the rate
of growth of melanomas, most melanomas can be cat-
egorized into 1 of 3 groups: very slow growing (ie, len-
tigomaligna [LM]), slowgrowing (ie, SSM), and fast grow-
ing (ie, NM).3
However, the theory of epidermal origin of melanoma
cannot adequately explain the absence of substantial epi-
dermal involvement (ie, lack of pagetoid spread) and lack
of a radial component (ie, radial spread confined towithin
3 rete ridges at either edge of the tumor) in NM.1 It is pre-
sumed that themalignantmelanocytes inNMproceed di-
rectly to rapid vertical growthwhile being incapable of hori-
zontal growth, perhaps owing to inherent properties of the
malignant cells or the tumormicroenvironment. These dis-
tinctive properties ofNMcells are poorly understood. Fur-
thermore, it is virtually impossible for the epidermal ori-
ginofmelanoma theory to account for theoriginof primary
dermal melanomas.4,5
Thus, it behooves us to explore an alternative hypoth-
esis that explains the origin and growth characteristics
of the different subtypes of melanoma. To this end, stem
cell research has opened up new and intriguing hori-
zons that may enable better understanding of develop-
ment of cancer in general and melanoma in particu-
lar.6-9 Stem cells are slowly proliferating self-renewing cells
that are able to differentiate into cell types of multiple
lineages (ie, multipotent stem cells) or of one lineage (ie,
unipotent stem cells). Researchers have identified stem
cells of melanocytic lineage in the human hair follicle,
the epidermis, and recently also in the dermis.10-12 Emerg-
ing evidence supports the theory that some cancers such
as breast cancer, melanoma, glioblastoma, and myeloid
leukemiamay arise from transformed stem cells.10,11 This
stem cell–derived cancer model purports that malig-
nant tumors are composed of relatively few cancer stem
cells that constantly renew themselves, thereby helping
to maintain a lifelong stem cell pool. In addition to self-
renewal, stem cells also differentiate into rapidly prolif-
erating transient amplifying cells or progenitor cells,which
in turn differentiate into themature cancer cells with lim-
ited proliferative potential.13
On the basis of the stem cell–derived cancer model
and the notable clinical, morphologic, and epidemio-
logic differences among various subtypes of melanoma,
we hypothesize that different melanomas arise from dis-
tinct types of cutaneous stem cells. We speculate that
LM, NM, and SSM derive from melanoma stem cells of
the outer sheet of the hair follicle, the dermal compart-
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Figure 2. Lentigo maligna. A, Clinical appearance. B, Dermoscopic examination revealed asymmetric pigmented hair follicles as the earliest sign of tumor growth
(arrow) (original magnification 10). C, At histopathologic analysis, melanocytes are arranged in nests and single units at the dermoepidermal junction. The
papillary dermis exhibits solar elastosis, scattered melanophages, and a sparse lymphoid infiltrate (hematoxylin-eosin, original magnification 40). D, Note the
prominent perifollicular arrangement of melanocytes at higher magnification (hematoxylin-eosin, original magnification 200).
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ment, and the epidermal basal layer, respectively
(Figure 1).
Chronic or intermittent sun exposure is widely
accepted to have a crucial role in the development of
LM and SSM, respectively, but does not seem to be a
key event in the pathogenesis of NM. Studies have
shown that NMs tend to develop in individuals who
otherwise do not have obvious melanoma risk factors
such as a family history of melanoma. These patients
tend to manifest only few nevi, freckles, and actinic
keratoses14; freckles are an accepted indicator of sun
exposure. To explain the basis for the different pheno-
typic traits in patients with NM and the distinct mor-
phologic appearance and biological behavior of NM, we
hypothesize that melanocytic stem cells residing in the
dermis, a location that receives negligible amounts of
UV radiation, undergo spontaneous mutations that lead
to the development of NM (Figure 1). The concept that
NM originates in the dermis also explains why melano-
mas arising in large congenital nevi, whose melanocytic
population extends deeply into the dermis and subcu-
tis, are often nodular and subepidermal in origin. In
contrast, stem cells in the hair follicles of chronically
sun-exposed skin and in the epidermis of intermittently
sun-exposed skin are at higher risk for acquiring
UV-induced mutations, leading to development of LM
and SSM, respectively.
In vivo observations at dermoscopy and reflectance-
mode confocal microscopy (RCM) have provided fur-
ther support for the concept that LM, NM, and SSM
have different origins. At dermoscopy, pigmented dots
around the hair follicles or the presence of asymmetric
pigmented hair follicular openings are the earliest signs
of LM (Figure 2), which suggests the follicular origin
of LM.15 The morphologic hallmark of early SSM in situ
is a pigment network pattern, which corresponds histo-
pathologically to an increased number of melanocytes
at the basal layer (Figure 3) and underscores an epi-
dermal origin for this melanoma subtype.16
The study by Segura et al1 in this issue of the
Archives is of particular interest because it lends support
to our hypothesis by showing important differences
between NM and SSM with secondary invasive nodular
components using RCM. In their study, NMs exhibited
relatively minor pagetoid spread within a relatively pre-
served epidermal architecture, in contrast to epidermal
disarrangement and abundant pagetoid infiltration
observed in nodules occurring in SSMs. Similar findings
are also seen at histopathologic analysis, revealing only
few scattered epidermal melanocytes over the dermal
tumor mass in NM (Figure 4) in contrast to the
marked epidermal disarray and the striking pagetoid
spread above the nodular component in SSM
(Figure 3).
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Figure 3. Superficial spreading melanoma. A, Clinical appearance. B, Dermoscopic examination exhibited a clearly discernible flat area around the nodular part. The flat
area shows a pigment network that corresponds histopathologically to melanocytes along the rete ridges of the basal layer (original magnification10). C, At
histopathologic analysis, secondary nodular superficial spreading melanoma exhibits a broad melanoma in situ component with atypical melanocytes in nest and single
cell formations within all epidermal layers, surrounding a central nodular melanoma component (hematoxylin-eosin, original magnification40). D, Note the atypical
melanocytes in higher layers of epidermis (pagetoid spread) above a nodular melanoma component (hematoxylin-eosin, original magnification100).
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We have hypothesized that NM is derived from der-
mal stem cells and that the other melanoma subtypes are
derived from epidermal stem cells. However, to better un-
derstand why NM growsmuchmore rapidly than LM or
SSM14 requires appreciation of the interaction of mela-
noma cells with surrounding cells and the tumor micro-
environment. As Lee and Herlyn stated, “An often over-
looked facet of tumor biology research is the involvement
of the surrounding tumor microenvironment. Increas-
ing evidence is being presented to support a major role
for stromal components in all stages of tumorigenesis in-
cluding initiation, progression, andmetastasis.”17(p862) Un-
der normal conditions, proliferation of epidermal mela-
nocytes is controlled by the surrounding keratinocytes.18
It is plausible that during the early stages of melanoma
development, proliferation of melanoma cells is slowed
by relatively intact keratinocyte-melanocyte interac-
tions. In contrast, keratinocytes are less likely able to regu-
late the proliferation of NM cells arising in the dermis.
In addition, difference in the composition of the dermal
stromamay furthermodify the rate of growth of LM,NM,
and SSM.19
In conclusion, evidence is mounting that different
melanoma subtypes may arise from distinct stem cells.
However, further basic science and clinical research is
required to help elucidate the exact origin of the differ-
ent melanoma subtypes.
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Type I Interferon in the Induction or Exacerbation
of Dermatomyositis
What This Observation Tells Us About the Naturally Occurring Disease
A DVERSE EVENTS ASSOCIATED WITH MEDI-cation use are a bane for physicians. How-ever, when an adverse effect goes be-yond an isolated clinical or laboratoryfinding and is instead a phenocopy of a
naturally occurring disease state, we are presented with
an opportunity to understand disease pathogenesis. The
less common situation in which a disease state is repro-
duced with a naturally occurring biologic substance (ie,
cytokine or hormone) makes even the most jaded of cli-
nicians stand up and take note. The association of sup-
raphysiologic amounts of an endogenous molecule with
an induced disease state hardly provides physiologic proof
of its connection in the spontaneously occurring dis-
ease, but it provides another level of evidence in a world
in which the study of human disease rarely affords one
with the opportunity to perform an in vivo experiment.
It is with this level of interest and caution that we should
approach the article in this issue of the Archives by So-
mani et al,1 in which the administration of interferon beta
is associated with new-onset dermatomyositis.
It has been more than 50 years since the discovery of
interferon (IFN) as an endogenously produced sub-
stance with potent antiviral properties.2 It is now clear
that IFNs are proteins that have a more general role in
innate and adaptive immunity, activating dendritic cells
and lymphocytes in the fight against many types of
infection, as well as having important roles in cellular
differentiation, proliferation, apoptosis, and more.3
There are 3 classes of IFNs, all of which are highly con-
served in vertebrates. Type I IFNs are a family of highly
related proteins consisting of (in humans) IFN- (13
subtypes), IFN-, IFN-, IFN-ε, and IFN-.4 They all
seem to signal via the same receptor, the type I IFN
receptor (IFNAR); therefore, their activities are similar
(potential differences in binding location and affinity
might account for small distinctions between the vari-
ous members). Virtually every cell is capable of pro-
ducing type I IFN, consistent with its activity as a first-
line agent for defense against viruses. This is in
contrast to type II IFN (IFN-), which is mainly pro-
duced by natural killer cells and activated T cells.
Type III IFNs are a newly discovered class consisting
of 3 members, IFN-1, IFN-2, and IFN-3, which
have overlapping activities with type I IFNs but signal
through a distinct receptor.4
The first interferon to be used in clinical medicine was
interferonalfa, introduced in1986 for the treatmentofhairy
cell leukemia.5 Today, preparations of interferon alfa and
interferon beta are used for chronic viral hepatitis B and
C, Kaposi sarcoma, Behc¸et disease, chronic myelogenous
leukemia, multiple myeloma, multiple sclerosis, and car-
cinoid syndrome, to name just a few. Most of us are fa-
miliar with the more common “flulike” symptoms asso-
ciated with interferon use, including fever, malaise,
myalgias, and the like. In addition, other nonspecific rashes
are observed following exposure to interferon, including
eczematous, lichenoid, vesicular, and ulcerative lesions.
Germane to this discussion, however, is the association
See also page 1341
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